HC Wainwright Reduces Earnings Estimates for Pyxis Oncology

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Equities research analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of Pyxis Oncology in a report released on Monday, May 19th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.36) per share for the quarter, down from their prior estimate of ($0.31). HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology's Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($0.60) EPS.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06).

Separately, Royal Bank of Canada reissued an "outperform" rating and set a $8.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Pyxis Oncology presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

Pyxis Oncology Stock Performance

NASDAQ PYXS traded up $0.03 on Wednesday, hitting $1.23. 471,961 shares of the stock traded hands, compared to its average volume of 739,771. The business's fifty day moving average is $1.06 and its two-hundred day moving average is $1.56. Pyxis Oncology has a 12 month low of $0.83 and a 12 month high of $5.39. The firm has a market capitalization of $76.20 million, a price-to-earnings ratio of -1.19 and a beta of 1.15.

Institutional Trading of Pyxis Oncology

Hedge funds have recently made changes to their positions in the stock. Barclays PLC boosted its position in shares of Pyxis Oncology by 275.0% in the 3rd quarter. Barclays PLC now owns 64,089 shares of the company's stock worth $235,000 after purchasing an additional 46,997 shares in the last quarter. American Century Companies Inc. lifted its position in Pyxis Oncology by 88.1% in the 4th quarter. American Century Companies Inc. now owns 299,937 shares of the company's stock valued at $468,000 after acquiring an additional 140,498 shares in the last quarter. Caption Management LLC bought a new position in Pyxis Oncology in the 4th quarter valued at approximately $35,000. Renaissance Technologies LLC lifted its position in Pyxis Oncology by 83.0% in the 4th quarter. Renaissance Technologies LLC now owns 293,354 shares of the company's stock valued at $458,000 after acquiring an additional 133,018 shares in the last quarter. Finally, Ridgeback Capital Investments L.P. bought a new position in Pyxis Oncology in the 4th quarter valued at approximately $560,000. 39.09% of the stock is owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.